Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Weight loss from GLP-1 medications does not produce a disproportionate reduction in muscle mass or function in either obese mice or humans
With the use of the ASOs to target the SCN1A NAT, one study was effectively able to rescue the sense SCN1A gene expression, ameliorate neuronal excitability and seizures in a mouse model of DSan effect that almost entirely recapitulates the rescued phenotypes observed via CRISPRa treatment [74, 75]
It's about finding a realistic plan you can follow consistentlyeven on your busiest days
Drug safety 22 , 123148 (2000)
US$ 20.52
US$ 26.56
US$ 22.00
US$ 21.18
US$ 22.31
US$ 22.33
US$ 21.36
